Schieker K R, Hofmann H F
Pharmatherapeutica. 1981;2(8):499-503.
A double-blind controlled trial was carried out to compare the efficacy of sisomicin and tobramycin in the treatment of 55 hospitalized patients with serious systemic infections, mostly intra-abdominal or soft-tissue infections. Each drug was administered intramuscularly or intravenously at a dosage of 2.5 to 4.0 mg/kg per day for between 5 and 21 days. At the end of treatment, 22 (79%) of 28 sisomicin-treated patients and 15 (72%) of 21 tobramycin-treated patients were assessed, on the basis of clinical and bacteriological response, as cured or partially cured. Sisomicin was superior in the treatment of Escherichia coli infections. Local tolerance to both drugs was good. The incidence of systemic adverse reactions was low, fewer cases occurring in the sisomicin treatment group than in the tobramycin treatment group.
进行了一项双盲对照试验，比较西索米星和妥布霉素治疗55例住院严重全身感染患者（主要为腹腔内或软组织感染）的疗效。每种药物均通过肌肉注射或静脉注射给药，剂量为每日2.5至4.0mg/kg，疗程为5至21天。治疗结束时，根据临床和细菌学反应评估，28例接受西索米星治疗的患者中有22例（79%）、21例接受妥布霉素治疗的患者中有15例（72%）被评定为治愈或部分治愈。西索米星在治疗大肠杆菌感染方面更具优势。两种药物的局部耐受性良好。全身不良反应的发生率较低，西索米星治疗组出现的病例比妥布霉素治疗组少。
